Advertisement

Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health Model

  • Sandra A. Springer
  • Frederick L. Altice

Highly active antiretroviral therapy (HAART) has remarkably transformed HIV disease into a chronic condition such that when patients completely suppress viral replication, they can expect to live a normal life expectancy. Unfortunately, many of those who might benefit most from HAART (e.g., illicit drug users, the mentally ill, and the socially and medically marginalized) are less likely to receive it, and when they do, less likely to adhere to treatment. Many of these individuals do not interface consistently with health care institutions in the community setting, yet when incarcerated, have an important opportunity not only to be identified as being HIV-infected, but also to initiate HAART if medically indicated. The prevalence of HIV infection among prisoners is five to seven times greater among incarcerated persons compared to the general population (Crosland, Poshkus, & Rich, 2002; Spaulding et al., 2002). Prisons and jails house individuals with HIV who have not traditionally benefited from access to HIV care and antiretroviral therapy in community settings. Specifically, prisons are comprised of HIV-infected individuals with comorbid medical conditions such as substance use disorder and serious psychiatric illnesses and are socially marginalized through relapsing homelessness, poverty, and unstable living circumstances. HIV care has resulted in impressive reductions in mortality in the New York prison system (CDC, 1999) and HIV/AIDS is no longer the leading cause of prison-related mortality nationally (Linder, Enders, Craig, Richardson, & Meyers, 2002). In nearby Connecticut where 98% of prescribed HAART regimens were within the Department of Health and Human Services guidelines, impressive increases in CD4 count and reductions in HIV-1 RNA levels were observed. Indeed, 59% of these prisoners achieved a viral load below the level of detection prior to release. Despite these successes, the one-quarter of subjects who were reincarcerated lost the viral load and CD4 benefits within 3 months after release to the community (Springer et al., 2004).

Keywords

Viral Load Substance Abuse Treatment Methadone Maintenance Treatment Correctional Facility Case Management Service 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altice, F., & Khoshnood, K. (1997). Transitional case management as a strategy for linking HIV-infected prisoners to community health and social services ( Project TLC). Paper presented at the Connecticut Department of Public Heath.Google Scholar
  2. Altice, F., Mezger, J. A., Hodges, J., Bruce, R. D., Marinovich, A., Walton, M. et al. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clin Infect Dis, 38(Suppl. 5), S376–387.PubMedCrossRefGoogle Scholar
  3. Altice, F. L., Friedland, G. H., & Cooney, E. L. (1999). Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS, 13, 957–962.PubMedCrossRefGoogle Scholar
  4. Altice, F. L., Mostashari, F., Selwyn, P. A., Checko, P. J., Singh, R., Tanguay, S., et al. (1998). Predictors of HIV infection among newly sentenced male prisoners. J Acquir Immune Defic Syndr Hum Retrovirol, 18, 444–453.PubMedGoogle Scholar
  5. Altice, F. L., Smith-Rohrberg, D., Bruce, R. D., Springer, S., & Friedland, G. (2007). Superiority of directly administered antiretroviral therapy compared to self-administered therapy among HIV-infected drug users enrolled in a six-month prospective, randomized controlled trial. JAMA, in press.Google Scholar
  6. Altice, F. L., Springer, S., Buitrago, M., Hunt, D. P., & Friedland, G. H. (2003). Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health, 80, 416–427.PubMedGoogle Scholar
  7. Babudieri, S., Aceti, A., D’Offizi, G. P., Carbonara, S., & Starnini, G. (2000). Directly observed therapy to treat HIV infection in prisoners. JAMA, 284, 179–180.PubMedCrossRefGoogle Scholar
  8. Badger, D., Vaughan, P., Woodward, M., & Williams, P. (1999). Planning to meet the needs of offenders with mental disorders in the United Kingdom. Psychiatr Serv, 50, 1624–1627.PubMedGoogle Scholar
  9. Beck, A., Karberg, J., & Harrison, P. (2002). Prison and jail inmates at midyear 2001. Retrieved from http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf
  10. Bouhnik, A. D., Chesney M., Carrieri, P., Gallais, H. et al. (2002). Nonadherence among HIV-infected injecting drug users: the impact of social instability. JAIDS 31, Supp 3, S149–153. Retrieved from http://www.ojp.usdoj.gov/bjs/pub/pdf/satsfp97.pdf
  11. Bruce, R. D., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2006). Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr, 41, 563–572.PubMedCrossRefGoogle Scholar
  12. Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., et al. (2003). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med, 10, 1–14.PubMedCrossRefGoogle Scholar
  13. CDC. (1999). Decrease in AIDS-related mortality in a state correctional system— New York, 1995–1998. MMWR, 47(51–52), 1115–1117.Google Scholar
  14. CDC. (2001). Helping inmates return to the community. Retrieved 2004 from www.cdc.gov/idu.
  15. Cloutier, G. (2002, July 7–21). Strategies to support treatment adherence in newly released HIV-positive prisoners. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.Google Scholar
  16. Conklin, T. J., Lincoln, T., & Flanigan, T. P. (1998). A public health model to connect correctional health care with communities. Am J Public Health, 88, 1249–1250.PubMedGoogle Scholar
  17. Crosland, C., Poshkus, M., & Rich, J. D. (2002). Treating prisoners with HIV/AIDS: The importance of early identification, effective treatment, and community follow-up. AIDS Clin Care, 14(8), 67–71, 76.PubMedGoogle Scholar
  18. Daar, E. S., Cohen, C., Remien, R., Sherer, R., & Smith, K. (2003). Improving adherence to antiretroviral therapy. AIDS Read, 13(2), 81–82, 85–86, 88–90.PubMedGoogle Scholar
  19. Dolan, K., Hall, W., & Wodak, A. (1996). Methadone maintenance reduces injecting in prison. BMJ, 312, 1162.PubMedGoogle Scholar
  20. Durand, E. (2001). [Changes in high-dose buprenorphine maintenance therapy at the Fleury-Merogis (France) prison since 1996]. Ann Med Interne (Paris), 152 (Suppl. 7), 9–14.Google Scholar
  21. Estebanez, P., Zunzunegui, M. V., Aguilar, M. D., Russell, N., Cifuentes, I. & Hankins, C. (2002). The role of prisons in the HIV epidemic among female injecting drug users. AIDS Care, 14, 95–104.PubMedCrossRefGoogle Scholar
  22. Feder, L. (1991). A comparison of the community adjustment of mentally ill offenders with those from general population: An 18-month follow-up. Law Hum Behav, 15, 477–493.CrossRefGoogle Scholar
  23. Fischl, M., Castro, J., & Monroig, R. (2001). Impact of directly observed therapy on long-term outcomes in HIV clinical trials. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Alexandria, VA.Google Scholar
  24. Flanigan, T. P., Kim, J. Y., Zierler, S., Rich, J., Vigilante, K., & Bury-Maynard, D. (1996). A prison release program for HIV-positive women: Linking them to health services and community follow-up. Am J Public Health, 86, 886–887.PubMedCrossRefGoogle Scholar
  25. Glaser, J. B., & Greifinger, R. B. (1993). Correctional health care: A public health opportunity. Ann Intern Med, 118, 139–145.PubMedGoogle Scholar
  26. Grinstead, O., Zack, B., & Faigeles, B. (2001). Reducing postrelease risk behavior among HIV seropositive prison inmates: The health promotion program. AIDS Educ Prev, 13, 109–119.PubMedCrossRefGoogle Scholar
  27. Hammett, T. M., Harmon, M. P., & Rhodes, W. (2002). The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health, 92, 1789–1794.PubMedCrossRefGoogle Scholar
  28. Holmes, L., Drainoni, M., & Rich, J. (2002, July). Harm reduction focused case management for multiply diagnosed HIV-positive ex-offenders. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.Google Scholar
  29. Homebase, P. (2006). Retrieved April 3, 2006, from www.sph.emory.edu/HIVCDP/california.htm.
  30. Hubbard, M. (2002, July). The effect of discharge planning on health outcomes for HIV-infected prison inmates. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.Google Scholar
  31. Kaplowitz, L., Kaatz, J., & Weir-Wiggins, C. (2002, July). Seamless transition of HIV+ inmates into community care in Virginia. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.Google Scholar
  32. Karberg, J., & James, D. (2005). Substance dependence, abuse, and treatment of jail inmates, 2002 (No. NCJ 209588). Washington , DC.Google Scholar
  33. Khalsa, J., Genser, S., Vocci, F., Francis, H., & Bean, P. (2002). The challenging interactions between antiretroviral agents and addiction drugs. Am Clin Lab, 21(3), 10–13.PubMedGoogle Scholar
  34. Kiefer, F., & Mann, K. (2005). New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol, 526(1–3), 163–171.PubMedCrossRefGoogle Scholar
  35. Kozal, M. J., Amico, K. R., Chiarella, J., Cornman, D., Fisher, W., Fisher, J., et al. (2005). HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr, 40, 106–109.PubMedCrossRefGoogle Scholar
  36. Kushel, M. B., Colfax, G., Ragland, K., Heineman, A., Palacio, H., & Bangsberg, D. R. (2006). Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis, 43, 234–242.PubMedCrossRefGoogle Scholar
  37. Laufer, F., Arriola, K., & Dawson-Rose, C. (2002). From jail to community: Innovative strategies to enhance continutity of HIV/AIDS care. The Prison Journal, 82, 84–100.CrossRefGoogle Scholar
  38. Levasseur, L., Marzo, J., Ross, N., & Blatier, C. (2002). Frequency of re-incarcerations in the same detention center: Role of substitution therapy. A preliminary retrospective analysis. Ann Med Interne, 153(3 Suppl.), 1S14–19.Google Scholar
  39. Linder, J. F., Enders, S. R., Craig, E., Richardson, J., & Meyers, F. J. (2002). Hospice care for the incarcerated in the United States: An introduction. J Palliat Med, 5, 549–552.PubMedCrossRefGoogle Scholar
  40. Longshore, D., Hsieh, S. C., & Anglin, M. D. (1994). Reducing HIV risk behavior among injection drug users: Effect of methadone maintenance treatment on number of sex partners. Int J Addict, 29, 741–757.PubMedGoogle Scholar
  41. Lovell, D., Gagliardi, G. J., & Peterson, P. D. (2002). Recidivism and use of services among persons with mental illness after release from prison. Psychiatr Serv, 53, 1290–1296.PubMedCrossRefGoogle Scholar
  42. Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16, 767–774.PubMedCrossRefGoogle Scholar
  43. Lucas, G. M., Mullen, B. A., Weidle, P. J., Hader, S., McCaul, M. E., & Moore, R. D. (2006). Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis, 42, 1628–1635.PubMedCrossRefGoogle Scholar
  44. Magura, S., Rosenblum, A., Lewis, C., & Joseph, H. (1993). The effectiveness of in-jail methadone maintenance. J Drug Issues, 23, 75–99.Google Scholar
  45. Margolis, A. D., MacGowan, R. J., Grinstead, O., Sosman, J., Kashif, I., & Flanigan, T. P. (2006). Unprotected sex with multiple partners: Implications for HIV prevention among young men with a history of incarceration. Sex Transm Dis, 33, 175–180.PubMedCrossRefGoogle Scholar
  46. Mason, B. J. (2003). Acamprosate and naltrexone treatment for alcohol dependence: An evidence-based risk-benefits assessment. Eur Neuropsychopharmacol, 13, 469–475.PubMedCrossRefGoogle Scholar
  47. Mattick, R., Ali, R., & White, J. (2002). Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98, 441–452.CrossRefGoogle Scholar
  48. Mumola, C. (1999). Substance abuse and treatment, state and federal prisoners, 1997. Retrieved from.Google Scholar
  49. Nelles, J., & Harding, T. (1995). Preventing HIV transmission in prison: A tale of medical disobedience and Swiss pragmatism. Lancet, 346, 1507–1508.PubMedCrossRefGoogle Scholar
  50. Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., & Samet, J. H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99, 361–368.PubMedCrossRefGoogle Scholar
  51. Palepu, A., Tyndall, M. W., Li, K., Yip, B., O’Shaughnessy, M. V., Schechter, M. T., et al. (2003). Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health, 80, 667–675.PubMedGoogle Scholar
  52. Pollard, R. B. (2002). Can HIV infection be treated successfully with a once-daily regimen? AIDS Read, 12(11), 489–490, 494–498, 500, 508.PubMedGoogle Scholar
  53. Rich, J. D., Holmes, L., Salas, C., Macalino, G., Davis, D., Ryczek, J., et al. (2001). Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health, 78, 279–289.PubMedGoogle Scholar
  54. Richie, B. E., Freudenberg, N., & Page, J. (2001). Reintegrating women leaving jail into urban communities: A description of a model program. J Urban Health, 78, 290–303.PubMedGoogle Scholar
  55. Roozen, H. G., de Waart, R., van der Windt, D. A., van den Brink, W., de Jong, C. A., & Kerkhof, A. J. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol, 16, 311–323.PubMedCrossRefGoogle Scholar
  56. Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D., & Kosten, T. R. (1997). Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry, 54, 713–720.PubMedGoogle Scholar
  57. Shuter, J. (2002). Communicable diseases in inmates; public health opportunities. Paper presented at the Health Status of Soon-to-be-Released Inmates.Google Scholar
  58. Sibbald, B. (2002). Methadone maintenance expands inside federal prisons. CMAJ, 167, 1154.PubMedGoogle Scholar
  59. Smith-Rohrberg, D., & Altice, F. L. (2006). Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: Questions about study population and analytical approach. Clin Infect Dis, 43, 1221–1222; author reply 1222–1223.PubMedCrossRefGoogle Scholar
  60. Smith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2004). Review of corrections-based therapy for opiate-dependent patients: Implications for buprenorphine treatment among correctional populations. J Drug Issues, 34, 451–480.Google Scholar
  61. Smith-Rohrberg, D., Kozal, M. J., Springer, S., & Altice, F. L. (submitted). Similar Rates of Genotypic Resistance Among HIV-Infected Drug Users Receiving Directly Administered Antiretroviral Therapy and Self-Administered Therapy: Results from a Six-Month Prospective, Randomized Controlled Trial. Unpublished Journal Article. Yale School of Medicine, Yale AIDS Program.Google Scholar
  62. Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr Hum Retrovirol, 43(Suppl. 1), S48–53.Google Scholar
  63. Sosman, J., Baker, J., & Catz, S. (2002). Clinical and immune recovery during antiretroviral therapy among HIV-infected prisoners. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.Google Scholar
  64. Spaulding, A., Stephenson, B., Macalino, G., Ruby, W., Clarke, J. G., & Flanigan, T. P. (2002). Human immunodeficiency virus in correctional facilities: A review. Clin Infect Dis, 35, 305–312.PubMedCrossRefGoogle Scholar
  65. Springer, S. A., & Altice, F. L. (2005). Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep, 2, 165–170.PubMedCrossRefGoogle Scholar
  66. Springer, S. A., Pesanti, E., Hodges, J., Macura, T., Doros, G., & Altice, F. L. (2004). Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis, 38, 1754–1760.PubMedCrossRefGoogle Scholar
  67. Stein, M. D., Solomon, D. A., Herman, D. S., Anderson, B. J., & Miller, I. (2003). Depression severity and drug injection HIV risk behaviors. Am J Psychiatry, 160, 1659–1662.PubMedCrossRefGoogle Scholar
  68. Stephenson, B. L., Wohl, D. A., Golin, C. E., Tien, H. C., Stewart, P., & Kaplan, A. H. (2005). Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep, 120, 84–88.PubMedGoogle Scholar
  69. Stephenson, B. L., Wohl, D. A., McKaig, R., Golin, C. E., Shain, L., Adamian, M., et al. (2006). Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS, 17, 103–108.PubMedCrossRefGoogle Scholar
  70. Theall, K., Clark, R., Powell, A., Smith, H., & Kissinger, P. (2006). Alcohol consumption, art usage and high-risk sex among women infected with HIV [Electronic Version]. AIDS and Behavior. Retrieved September 18, 2006.Google Scholar
  71. Thompson, A. S., Blankenship, K. M., Selwyn, P. A., Khoshnood, K., Lopez, M., Balacos, K., et al. (1998). Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. J Community Health, 23, 419–440.PubMedCrossRefGoogle Scholar
  72. Tomasino, V., Swanson, A. J., Nolan, J., & Shuman, H. I. (2001). The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. Mt Sinai J Med, 68, 14–20.PubMedGoogle Scholar
  73. Tucker, J. S., Burnam, M. A., Sherbourne, C. D., Kung, F. Y., & Gifford, A. L. (2003). Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med, 114, 573–580.PubMedCrossRefGoogle Scholar
  74. Turner, B. J., Fleishman, J. A., Wenger, N., London, A. S., Burnam, M. A., Shapiro, M. F., et al. (2001). Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med, 16, 625–633.PubMedCrossRefGoogle Scholar
  75. Tyndall, M. W., Patrick, D., Spittal, P., Li, K., O’Shaughnessy, M. V., & Schechter, M. T. (2002). Risky sexual behaviours among injection drugs users with high HIV prevalence: Implications for STD control. Sex Transm Infect, 78(Suppl. 1), i170–175.PubMedCrossRefGoogle Scholar
  76. WHO. (1993). World Health Organization guidelines on HIV infection and AIDS in prison. Strasbourg: Council of Europe: Ministers of the State Members.Google Scholar
  77. Williams, S. H. (2005). Medications for treating alcohol dependence. Am Fam Physician, 72, 1775–1780.PubMedGoogle Scholar
  78. Wohl, A. R., Garland, W. H., Valencia, R., Squires, K., Witt, M. D., Kovacs, A., et al. (2006). A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis, 42, 1619–1627.PubMedCrossRefGoogle Scholar
  79. Wolff, N. (2005). Community reintegration of prisoners with mental illness: A social investment perspective. Int J Law Psychiatry, 28, 43–58.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Sandra A. Springer
    • 1
  • Frederick L. Altice
    • 2
  1. 1.Yale AIDS Program, Section of Infectious DiseasesYale School of MedicineNew HavenUSA
  2. 2.Yale University AIDS ProgramNew HavenUSA

Personalised recommendations